These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 9762359)

  • 41. Microenvironmental and cellular consequences of altered blood flow in tumours.
    Raghunand N; Gatenby RA; Gillies RJ
    Br J Radiol; 2003; 76 Spec No 1():S11-22. PubMed ID: 15456710
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A paradigm for therapy-induced microenvironmental changes in solid tumors leading to drug resistance.
    Yu JL; Coomber BL; Kerbel RS
    Differentiation; 2002 Dec; 70(9-10):599-609. PubMed ID: 12492501
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Inhibition of vascular endothelial growth factor (VEGF) as a novel approach for cancer therapy.
    Wood JM
    Medicina (B Aires); 2000; 60 Suppl 2():41-7. PubMed ID: 11188930
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Interstitial fluid pressure in cervical cancer: guide to targeted therapy.
    Milosevic M; Fyles A; Hill R
    Am J Clin Oncol; 2001 Oct; 24(5):516-21. PubMed ID: 11586107
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Overcoming tumor hypoxia as a barrier to radiotherapy, chemotherapy and immunotherapy in cancer treatment.
    Graham K; Unger E
    Int J Nanomedicine; 2018; 13():6049-6058. PubMed ID: 30323592
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Revisiting tumor angiogenesis: vessel co-option, vessel remodeling, and cancer cell-derived vasculature formation.
    Qian CN; Tan MH; Yang JP; Cao Y
    Chin J Cancer; 2016 Jan; 35():10. PubMed ID: 26747273
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Vascular targeting therapy: potential benefit depends on tumor and host related effects.
    Horsman MR; Bohn AB; Busk M
    Exp Oncol; 2010 Sep; 32(3):143-8. PubMed ID: 21403608
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Microvascular endothelial cell heterogeneity: general concepts and pharmacological consequences for anti-angiogenic therapy of cancer.
    Langenkamp E; Molema G
    Cell Tissue Res; 2009 Jan; 335(1):205-22. PubMed ID: 18677515
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Clinical experience with angiogenesis signaling inhibitors: focus on vascular endothelial growth factor (VEGF) blockers.
    Rosen LS
    Cancer Control; 2002; 9(2 Suppl):36-44. PubMed ID: 11965229
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Vascular abnormalities and development of hypoxia in microscopic melanoma xenografts.
    Gaustad JV; Simonsen TG; Andersen LMK; Rofstad EK
    J Transl Med; 2017 Nov; 15(1):241. PubMed ID: 29183378
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Eradication of large solid tumors in mice with an immunotoxin directed against tumor vasculature.
    Burrows FJ; Thorpe PE
    Proc Natl Acad Sci U S A; 1993 Oct; 90(19):8996-9000. PubMed ID: 7692443
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Hyperbaric oxygen therapy for malignancy: a review.
    Daruwalla J; Christophi C
    World J Surg; 2006 Dec; 30(12):2112-31. PubMed ID: 17102915
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Neovasculature induced by vascular endothelial growth factor is fenestrated.
    Roberts WG; Palade GE
    Cancer Res; 1997 Feb; 57(4):765-72. PubMed ID: 9044858
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Selective targeting of angiogenic tumor vasculature by vascular endothelial-cadherin antibody inhibits tumor growth without affecting vascular permeability.
    Liao F; Doody JF; Overholser J; Finnerty B; Bassi R; Wu Y; Dejana E; Kussie P; Bohlen P; Hicklin DJ
    Cancer Res; 2002 May; 62(9):2567-75. PubMed ID: 11980651
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Novel anti-angiogenic therapies for malignant gliomas.
    Norden AD; Drappatz J; Wen PY
    Lancet Neurol; 2008 Dec; 7(12):1152-60. PubMed ID: 19007739
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Disparate effects of endostatin on tumor vascular perfusion and hypoxia in two murine mammary carcinomas.
    Fenton BM; Paoni SF; Grimwood BG; Ding I
    Int J Radiat Oncol Biol Phys; 2003 Nov; 57(4):1038-46. PubMed ID: 14575835
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Targeting Angiogenesis in Cancer Therapy: Moving Beyond Vascular Endothelial Growth Factor.
    Zhao Y; Adjei AA
    Oncologist; 2015 Jun; 20(6):660-73. PubMed ID: 26001391
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Vascular-targeting therapies for treatment of malignant disease.
    Siemann DW; Chaplin DJ; Horsman MR
    Cancer; 2004 Jun; 100(12):2491-9. PubMed ID: 15197790
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Intermittent hypoxia induces a metastatic phenotype in breast cancer.
    Chen A; Sceneay J; Gödde N; Kinwel T; Ham S; Thompson EW; Humbert PO; Möller A
    Oncogene; 2018 Aug; 37(31):4214-4225. PubMed ID: 29713057
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Towards the virtual tumor for optimizing radiotherapy treatments of hypoxic tumors: A novel model of heterogeneous tissue vasculature and oxygenation.
    Schiavo F; Kjellsson Lindblom E; Toma-Dasu I
    J Theor Biol; 2022 Aug; 547():111175. PubMed ID: 35644483
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.